Meta- analysis of RCTs showed that only cyclosporine A provided a simultaneous great effect size of SMD on ICSI , pain , and frequency .
Amitriptyline at different dosages showed a great effect size of SMD on pain and urgency or on ICSI and frequency .
The results from the n RCTs showed that the most frequently adopted treatment is oral pentosan polysulfate and that the use of botulinum A toxin intradetrusorial injections in PBS/IC is increasing .
Limited evidence exists for the few treatments for PBS/IC .
The lack of definitive conclusions is due to the great heterogeneity in methodology , symptoms assessment , duration of treatment , and follow-up in both RCTs and n RCTs
CONTEXT Different types of behavioural , dietary , interventional , pharmacologic , and surgical therapies have been used to treat painful bladder syndrome/interstitial cystitis ( PBS/IC ) .
Because of the paucity of r and omised placebo-controlled studies on different treatments , an evidence -based management approach has not yet been developed .
OBJECTIVE To critically review and synthesize data from a wide range of current therapeutic approaches to PBS/IC , to quantify the effect size from r and omised controlled trials ( RCTs ) , and to reach clinical agreement on the efficacy of treatments for PBS/IC .
Intravesical Bacillus Calmette-Guerin for treatment of refractory interstitial cystitis.
INTRODUCTION The aim of this study was to examine the efficacy and safety of intravesical Bacillus Calmette-Guerin ( BCG ) in the treatment of refractory interstitial cystitis ( IC ) . MATERIAL S AND METHODS Thirteen patients with refractory IC were enrolled in the study . They were scheduled to receive 6 weekly courses of treatment with intravesical BCG . Variables including the frequency , nocturia , urgency , pelvic pain , dyspareunia , dysuria , IC symptom index , IC problem index , and average voided volume were assessed every 6 months after the BCG therapy . RESULTS Thirteen patients received the complete course of intravesical BCG therapy . Twenty-four months after the treatment a mean improvement of 51.9 % was seen in frequency ( P=.001 ) , 43.2 % in nocturia ( P=.002 ) , 28.7 % in urgency ( P=.004 ) , 43.1 % in pelvic pain ( P=.001 ) , 58.3 % in dyspareunia ( P=.003 ) , 6.5 % in dysuria ( P=.16 ) , 57.7 % in the O'Leary-Sant IC symptom index ( P=.001 ) , and 61.8 % in the O'Leary-Sant IC problem index ( P=.001 ) scores . A significant improvement was seen in the mean average voided volume at the 24th follow-up month ( 89.5 % ; P=.001 ) . CONCLUSION Intravesical BCG is a relatively effective treatment in patients with refractory IC . Its efficacy seems to be modest and lasts for at least 24 months in majority of the patients . It is also safe and well tolerated
Meta- analysis of RCTs showed that only cyclosporine A provided a simultaneous great effect size of SMD on ICSI , pain , and frequency .
Amitriptyline at different dosages showed a great effect size of SMD on pain and urgency or on ICSI and frequency .
The results from the n RCTs showed that the most frequently adopted treatment is oral pentosan polysulfate and that the use of botulinum A toxin intradetrusorial injections in PBS/IC is increasing .
Limited evidence exists for the few treatments for PBS/IC .
The lack of definitive conclusions is due to the great heterogeneity in methodology , symptoms assessment , duration of treatment , and follow-up in both RCTs and n RCTs
CONTEXT Different types of behavioural , dietary , interventional , pharmacologic , and surgical therapies have been used to treat painful bladder syndrome/interstitial cystitis ( PBS/IC ) .
Because of the paucity of r and omised placebo-controlled studies on different treatments , an evidence -based management approach has not yet been developed .
OBJECTIVE To critically review and synthesize data from a wide range of current therapeutic approaches to PBS/IC , to quantify the effect size from r and omised controlled trials ( RCTs ) , and to reach clinical agreement on the efficacy of treatments for PBS/IC .